Generalized anxiety disorder (GAD), the most frequently diagnosed form of anxiety, is
usually treated by cognitive-behavioural approaches or medication; in particular …

Background: Agomelatine is a novel agent that acts on melatonergic (MT 1, MT 2) receptors
and serotonergic (5-HT 2C) receptors. Preclinical data and data from clinical trials in major …

Introduction: Generalized anxiety disorder (GAD) is a chronic and disabling disorder with a
lifetime prevalence of 4.3–5.9% in the general population. Many drug and non-drug …

Agomelatine is an antidepressant with a novel mechanism of being a selective melatonergic
MT₁/MT₂ receptor agonist with serotonin 5-HT 2c receptor antagonist activities. Although …

Introduction: Agomelatine is a melatonergic antidepressant, approved for the treatment of
Major Depressive Disorder (MDD) in Europe and Australia, but not in the United States. This …

Introduction: Preliminary data indicate agomelatine as a promising molecule for both acute
and long-term treatment of generalised anxiety disorder (GAD). Areas covered: The present …

Agomelatine is efficacious in reducing symptoms and preventing relapse in placebo-
controlled trials in generalised anxiety disorder (GAD). Nevertheless, fixed dose studies of …

Anxiety disorders (ADs) are the most common type of psychiatric disorders. Pharmacologic
options studied for treating ADs may include benzodiazepines, tricyclic antidepressants …

Introduction The purpose of this study is to investigate the effects of agomelatine on anxious
symptoms and functional impairment in a pooled dataset from randomized placebo …

Background Although many generalized anxiety disorder (GAD) patients respond to the
available pharmacological treatments, nearly half of them do not present the expected …